TIDMSENS

RNS Number : 0276S

Sensyne Health PLC

12 March 2021

Agreement with the UK Department of Health & Social Care to pilot Sensyne Health's MagnifEye Ô technology for use with COVID-19 lateral flow diagnostic tests

Oxford, U.K. 12 March 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the British Clinical AI technology company, today announces it has signed a GBP470,000 agreement with the Department of Health & Social Care to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.

The agreement with the Department of Health & Social Care follows an announcement made by Sensyne on 09 February 2021 that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests .

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"We are delighted to be working with the Department of Health & Social Care and Excalibur and are happy to be able to contribute to the UK's COVID-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests and look forward to the results of this pilot study."

-ENDS-

For more information please contact:

 
  Sensyne Health ( www.sensynehealth.com             +44 (0) 330 058 
   )                                                  1845 
  Lord (Paul) Drayson PhD FREng, Chief Executive 
   Officer 
  Dr Richard Pye, Chief Financial Officer 
 
    Peel Hunt LLP (Nominated Adviser and Joint         + 44 (0) 20 7418 
    Broker)                                            8900 
  Dr Christopher Golden 
  James Steel 
  Oliver Jackson 
                                                     + 44 (0) 20 3100 
  Liberum (Joint Broker)                              2000 
  Bidhi Bhoma 
  Euan Brown 
                                                     +44 (0) 20 3709 
  Consilium Strategic Communications                  5700 
  Mary-Jane Elliott 
  Sukaina Virji 
  Davide Salvi 
  CSCS ensynehealth@consilium-comms.com 
 
   About Sensyne Health   www.sensynehealth.com .

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. This work uses data provided by patients and collected by the NHS as part of their care and support. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

About MagnifEye

The MagnifEye system ("the System") is Sensyne's proprietary software application available as both a smartphone app and a web application, that uses a cloud-based deep learning algorithm to automate the reading and analysis of different diagnostic tests including lateral flow tests. The System has been adapted to Excalibur's already high-performance lateral flow Antigen test. The System trains users to administer a lateral flow test, then interpret that test and provide a shareable digital certificate that validates the training of the user, the test result and resulting health status. It is anticipated that this will facilitate frequent testing, both for COVID-19 and a range of other conditions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRKFLFFFXLEBBL

(END) Dow Jones Newswires

March 12, 2021 02:00 ET (07:00 GMT)

Sensyne Health (LSE:SENS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sensyne Health Charts.
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sensyne Health Charts.